DAEWOONG CO.,LTD
Founded in 1961 and listed in 1973, Daewoong is a KOSPI holding company managing 35 subsidiaries including Daewoong Pharmaceutical.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureEstablished in 1961 and listed on the KOSPI in 1973, Daewoong Co., Ltd. is a holding company whose subsidiaries include Daewoong Pharmaceutical, Daewoong Bio, and HanAll Biopharma. Its core businesses are investment activities and management services, and as of December 31, 2025 it held a total of 35 subsidiaries, including Daewoong Pharmaceutical, Daewoong Bio, and HanAll Biopharma. Operating revenue consists of service fees, royalties, and dividends collected from subsidiaries and other invested companies; in its 66th fiscal term (2025), consolidated revenue reached KRW 2.0684 trillion (up 6.8% year-on-year), operating profit was KRW 261.8 billion (down 7.1%), and net income was KRW 227.9 billion (up 231.0%).
Regulatory approvals
data.go.kr12 Korean MFDS device approvals · 2002–2005
- MFDS의료용물질생성기Revoked2005-04-09Product approval · Class 2제허 05-255 호
- MFDS개인용온열기Revoked2005-01-25Product approval · Class 2제허 05-69 호
- MFDS의료용진동기Revoked2004-12-24Product approval · Class 2제허 04-1280 호
- MFDS의료용진동기Revoked2004-10-20Product approval · Class 2제허 04-1074 호
- MFDS개인용조합자극기Revoked2004-08-17Product approval · Class 2제허 04-854 호
- MFDS개인용조합자극기Revoked2003-06-02Product approval · Class 2제허 03-467 호
- MFDS개인용온열기Revoked2002-12-09Product approval · Class 2제허 02-943 호
- MFDS개인용조합자극기Revoked2002-11-22Product approval · Class 2제허 02-906 호
- MFDS의료용진동기Revoked2002-09-02Product approval · Class 2제허 02-715 호
- MFDS개인용조합자극기Revoked2002-08-27Product approval · Class 2제허 02-696 호
- MFDS의료용진동기Revoked2002-06-28Product approval · Class 2제허 02-531 호
- MFDS개인용조합자극기Revoked2002-03-20Product approval · Class 2제허 02-232 호
Clinical trials
data.go.kr7 MFDS clinical trial authorisations · 2012–2017 (Bioequivalence 5 · Phase 1 1 · Phase 3 1)
- Phase 1메트포르민염산염, 아토르바스타틴칼슘2017-02-07
1 trial site
- Phase 3메트포르민염산염, 아토르바스타틴칼슘2015-03-19
36 trial sites
- BioequivalenceDWJ1333-1정2014-05-01
2 trial sites
- Bioequivalence대웅올메사탄플러스정20/12.5밀리그램2013-12-10
2 trial sites
- BioequivalenceDWJ1334정 20밀리그램(올메사탄메독소밀)2013-12-03
2 trial sites
- BioequivalenceDWJ1333정2013-09-04
- Bioequivalence대웅콜린알포세레이트연질캡슐 400mg2012-07-31
2 trial sites
Companies approved for the same productsMedical Devices
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Alpha AI, founded in 1995 and KOSDAQ-listed in 2000, manufactures biocompatible metal implants and surgical instruments.
KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.
Founded in 2010 and KOSDAQ-listed in 2018, Dynamic Solution makes AI/IoT-based rehabilitation devices like the Rapael Smart Glove.
Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.
Founded in 2000 and KOSDAQ-listed in 2013, i-SENS makes blood glucose monitors and point-of-care testing devices.
Founded in 2010 and KOSDAQ-listed in 2018, Sejong Medical manufactures laparoscopic surgical instruments.
Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.
Founded in 2015 and listed on KOSDAQ in 2022, Noul develops the on-device AI diagnostic platform miLab™ for blood and cancer testing.
KOSDAQ-listed manufacturer of diagnostic X-ray imaging systems and core components such as generators and tubes.
KOSDAQ-listed molecular genetic diagnostics company providing NGS-based non-invasive prenatal testing (NIPT) under the MomGuard brand.
Founded in 2000 and KOSDAQ-listed in 2013, Corentec makes artificial joints; hip and knee implants exceed 85% of revenue.
Established in 2012 and listed on KOSDAQ in 2018, Osteonic manufactures implants for the CMF, Trauma, Sports Medicine, and Spine categories.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition